



## Notice Regarding Adjustment of 340B Prices for Select Products of SK Life Science, Inc.

SK Life Science, Inc. has recalculated its 340B ceiling prices for the period from July 1, 2022, through June 30, 2023, for the products listed below due to revisions made to their Medicaid pricing data. SK Life Science, Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about SK Life Science, Inc.'s recalculation affecting certain 340B Covered Entities for the impacted products.

SK Life Science, Inc. has determined the credit amount owed to each affected covered entity. SK Life Science, Inc. will be working through Apexus to issue refunds for each affected Covered Entity with a refund amount that is equal to or over \$50. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check or ACH will be issued to Covered Entities whose wholesaler account cannot be identified.

NDC	Product Description
7169905030	XCOPRI CENOBAMATE 50MG TABLET 30 CT
7169910030	XCOPRI CENOBAMATE 100MG TABLET 30 CT
7169915030	XCOPRI CENOBAMATE 150 MG TABLET 30CT
7169920030	XCOPRI CENOBAMATE 200 MG TABLET 30CT
7169920128	XCOPRI CENOBAMATE 12.5MG 25MG TITRATION
7169920228	XCOPRI CENOBAMATE 50MG 100MG TITRATION
7169920328	XCOPRI CENOBAMATE 150MG 200MG TITRATION

If a Covered Entity believes they are due a refund and are not contacted by 9/30/2024, you may contact SK Life Science, Inc at [qzhang@sklsi.com](mailto:qzhang@sklsi.com). Include in the subject line that this is a "340B Reimbursement" and include your entity's 340B ID. In addition, please include Invoice Date, Wholesaler Purchased from, Quantity Purchased, Invoiced Amount, and Purchase Invoice Number in the body of your email so that we can research your inquiry and reimburse, as necessary.